Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06279065 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Investigation of the Influence of the Human Microbiome on Giant Cell Arteritis

Study acronym: GCA-Biom
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated May 9, 2024 (before its estimated February 18, 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date changed from estimate of Feb 18, 2024 to Feb 29, 2024
    • Eligibility criteria expanded, about 8 words
    • Secondary endpoints revised (2)
    • Study title shortened, about 6 words
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The longitudinal observational study aims to assess the impact of the microbiome especially the gut-microbiome in the emergence and course of giant cell arteritis (abbr. GCA) patients. At diagnosis and 6 month follow up we will analyze the oral, blood and gut microbiome from GCA patients and healthy controls. Thereby identified potential candidate biota will be further analyzed for possible interactions and influence on the immune system.
Trial Details
NCT Number NCT06279065
Lead Sponsor University of Bonn
Conditions
(from sponsor)		 Giant Cell Arteritis
Related terms Giant Cell Arteritis
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov